Gonadothropin-releasing hormone agonist as a treatment of choice for central precocious puberty
DOI:
https://doi.org/10.13181/mji.v19i4.418Abstract
Precocious puberty is defi ned as pubertal development which occurs too early. The age limit in this term is based on the onset of puberty in normal population. Some points have to be taken into account, such as ethnicity, gender, nutritional conditions, and secular trends. In girls, precocious puberty is defi ned by breast development occured before 8 years old. In boys, precocious puberty is defi ned as gonadarche or pubarche before 9 years of age. The clinical course of precocious puberty varies widely, ranging from alternating, slowly progressive, and rapidly progressive   form. The rapidly progressive forms of idiopathic central precocious puberty need to be treated because it may result in early epiphyseal closure and short fi nal height, and also pyschosocial problems in the affected children and the family. The aims of treatment are to arrest physical maturation, prevent early menarche, and also improve adult height combined with normal body proportions. Gonadotropin releasing hormone analogue is the treatment of choice for central precocious puberty. Gonadotropin releasing horomone analogue has suppressive effect on the pituitarygonadal axis, therefore it suppresses LH secretion. This leads to the return of estradiol and testosterone to prepubertal levels. Treatment using gonadotropin releasing horomone analogue is shown to reduce breast size, pubic hair, ovarian and uterine size in girls, and decrease testicular size in boys. Gonadotropin releasing hormone analogue is effective in halting progression of secondary sexual characteristics development, presenting menstrual cycle, slowing bone-age advancement, and also improving fi nal height. (Med J Indones 2010; 19:287-92)
Keywords: gonadache, GRH analogue, pubarche , precocious puberty
Downloads
References
Partsch CJ, Sippell WG. Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Human Reproduction Update 2001;7(3):292-302
Parent AS, Teilmann G, Juul A, Skakkebaek NE, Toppari J, Bourguignon JP. The timing of normal puberty and the age limits of sexual precocity: variations araound the world, secular trends, anda changes after migration. Endocrine Reviews 2003;24(5):668-93
Teilmann G, Pedersen CB, Jensen TK, Skakkebek NE, Juul A. Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics 2005;116(6):1323-8
Hirsch HD, Gillis D, Strich D, Chertin B, Farkas A, Lindenberg T. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116; 798-802
Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: fi nal height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999;4(12):4583-90
Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clinical Endocrinology 2002;56(2):129-48
Carel JC, Leger J. Precocious puberty. N Engl J Med. 2008;358:2366-77
Fahmy JL, Kaminsky CK, Kaufman F, Nelson MD, Parisi MT. The radiological approach to precocious puberty. Br J Radiol. 2000;73:560-7
Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C, Brauner R. Central precocious puberty: clinical and laboratory features. Clinical Endocrinology. 2001;54:289-94
Stanhope R, Traggiai C. Precocious puberty (complete, partial). Sultan C (ed): Pediatric and Adolescent Gynecology. Evidence-Based Clinical Practice. Endocr Dev. Basel, Karger, 2004, vol 7, pp 57-65
Casper RF. Clinical uses of gonadotropin-releasing hormone analogues. Can Med Assoc J. 1991;144(2):153-8
Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006;91(5):1862-7
Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25mg). J Clin Endocrinol Metab. 2002;87(9):4111-6
Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB. Increased fi nal height in precocious puberty after long-term treatment with LHRH agonists: The National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86(10):4711-6
Micillo M, Salerno M, Offi cioso A, et al. Near fi nal height after GnRH agonist treatment in central precocious puberty. J Pediatr Endocrinol Metab. 2000;13(Suppl 1):787-90
Cassio A, Cacciari E, Balsamo A, Bal M, Tassinari D. Randomized trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years. Arch Dis Child. 1999; 81:329-32
Bouvattier C, Coste J, Rodrigue D, et al. Lack of effect of GnRH agonists on fi nal height in girls with advanced puberty: a randomized long-term pilot study. J Clin Endocrinol Metab. 1999; 84:3575-8
Diaz A, Danon M. Recent advances in the diagnosis and treatment of precocious puberty. Indian J Pediatr. 2000;67(3):211-5
Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol. 2000;163:838-44
Kim HS. Clinical application of gonadotropin-releasing hormone analogs in children and adolescents. Korean J Pediatr. 2010;53(3):294-9
Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropinreleasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function. J Clin Endocrinol Metab. 2007;93(1):190-5
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
